Table 4

Effects of alogliptin on markers of renal function, inflammation, and endothelial injury

nAlogliptin treatment groupnConventional treatment groupP value
eGFR (mL/min/1.73 m2)16178 ± 2016177 ± 180.59
 Change from baseline
  26 weeks 156−1 ± 101601 ± 90.025
  52 weeks154−1 ± 91571 ± 110.18
  78 weeks152−1 ± 101570 ± 110.44
  104 weeks150−1 ± 101530 ± 100.27
UAE at baseline (mg/g creatinine)15814.0 (7.8, 54.2)16015.8 (7.4, 46.5)0.96
 Change from baseline
  26 weeks 1030.6 (−5.0, 8.6)1110.8 (−3.5, 18.5)0.14
  52 weeks144−0.3 (−9.2, 5.2)1410.7 (−4.4, 7.5)0.067
  78 weeks128−1.0 (−9.2, 5.1)1191.0 (−4.1, 13.8)0.014
  104 weeks1450.3 (−5.3, 8.8)1440.4 (−5.1, 14.0)0.48
hs-CRP (ng/dL)158443 (209, 924)161545 (244, 868)0.42
 Change from baseline
  52 weeks14569 (−65, 245)15323 (−189, 280)0.28
  104 weeks14656 (−103, 250)15313 (−205, 200)0.18
Interleukin-6 at baseline (ng/dL)1582.1 (1.4, 2.7)1602.2 (1.5, 2.9)0.26
 Change from baseline
  52 weeks1450.0 (−0.7, 0.6)153−0.3 (−0.9, 0.4)§0.041
  104 weeks1450.1 (−0.3, 0.7)*1470.0 (−0.6, 0.6)0.12
ICAM-1 at baseline (ng/mL)158230 (187, 286)160218 (185, 297)0.35
 Change from baseline
  52 weeks145−2 (−28, 31)153−6 (−26, 20)0.62
  104 weeks144−6 (−37, 22)*147−9 (−39, 10)0.42
VCAM-1 at baseline (ng/mL)148664 (551, 821)160718 (580, 879)0.065
 Change from baseline
  52 weeks14532 (−78, 101)1539 (−68, 89)0.45
  104 weeks14520 (−57, 90)*147−8 (−102, 81)0.030
  • Data are mean ± SD or median (interquartile range). Differences in parameters between the groups at baseline were analyzed by the Student t test or the Wilcoxon rank sum test. Differences in parameters from baseline to 52 and 104 weeks within the group were analyzed by the one-sample t test or the Wilcoxon signed rank test. Differences in parameters from baseline to 52 and 104 weeks between the groups were analyzed by the Student t test or the Wilcoxon rank sum test.

  • ICAM-1, intercellular adhesion molecule 1; UAE, urinary albumin excretion.

  • *P < 0.05;

  • §P < 0.001.